Takeda Gains European Commission Clearance for ADZYNMA (Recombinant ADAMTS13), the First Recombinant ADAMTS13 Therapy for cTTP.

The FDA has approved Servier's VORANIGO® (vorasidenib) tablets as the first targeted treatment for Grade 2 IDH-mutant glioma.

NeuroBo Pharmaceuticals, Dong-A ST, and ImmunoForge Sign Agreement to Collaborate on Developing a Monthly DA-1726 Formulation to Treat Obesity.

Aug 9th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

The initial participant in the U.S. joins the phase III global multi-center clinical trial for telitacicept targeting myasthenia gravis, marking a significant milestone.

Elevation Oncology Releases Encouraging Early Results from Phase 1 Trial of EO-3021 in Patients with Advanced Non-Resectable or Metastatic Solid Tumors.

This expansion now encompasses Merck’s investigational product MK-6070, a T-cell engager targeting delta-like ligand 3 (DLL3).

Equillium Reports Favorable Interim Results from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease.

Global pharma major Lupin Limited, revealed the introduction of its first biosimilar in Canada, Rymti®, via its collaborator, Sandoz Canada.

Global Pharma major Lupin Limited revealed the completion of an international Phase 3 clinical trial for its biosimilar LUBT010.

On July 26, Belgian biotech company Confo Therapeutics (Confo) announced that it has completed a €60 million Series B financing round.

Levicept Reveals Successful Phase II Trial Results for LEVI-04, a Novel Neurotrophin-3 Inhibitor, in Treating Moderate to Severe Osteoarthritis.